FIGURE 7.

SMAD2/SAMD4 complex mediates transcriptional activation of JHDM1D/KDM7A in breast cancer cells. (A) MCF7 (left panel) and T47D cells (left panel) were treated with TGF-β and harvested at indicated time points. KDM7A expression was examined by qPCR and Western blotting. ChIP assay was performed with anti-SMAD2, anti-SMAD3, anti-SMAD4, or IgG. (B) MCF7 (left panel) and T47D cells (left panel) were treated with TGF-β and harvested at indicated time points. KDM7A expression was examined by qPCR and Western blotting. Re-ChIP assay was performed with indicated antibodies. (C,D) MCF7 (left panel) and T47D cells (left panel) were transfected with siRNAs targeting SMAD or scrambled siRNA followed by treatment with TGF-β. KDM7A expression was examined by qPCR and Western blotting. All experiments were performed in triplicate wells and repeated three times, and one representative experiment is shown. Data represent mean ± SD. *p < 0.05, two-tailed t-test. (E) Expression data were extracted from the public database to draw the scatter plot. Pearson correlation coefficient was calculated. Positive correlation between KDM7A expression and SMAD2/3/4 expression was identified in human breast cancer tissues.